Burkholderia cepacia epidemiology and pathogenesis: Implications for infection control

Current Opinion in Pulmonary Medicine

Volumn 4, Issue 6, 1998, Pages 337-341

  LiPuma, John J ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

BACTERIAL INFECTION; BURKHOLDERIA CEPACIA; COMORBIDITY; CYSTIC FIBROSIS; DRUG EFFECT; FEMALE; HUMAN; INCIDENCE; INFECTION CONTROL; ISOLATION AND PURIFICATION; MALE; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; OPPORTUNISTIC INFECTION; PROGNOSIS; REVIEW; RISK FACTOR;

ANTI-BACTERIAL AGENTS; BURKHOLDERIA CEPACIA; BURKHOLDERIA INFECTIONS; COMORBIDITY; CYSTIC FIBROSIS; FEMALE; HUMANS; INCIDENCE; INFECTION CONTROL; MALE; MICROBIAL SENSITIVITY TESTS; OPPORTUNISTIC INFECTIONS; PROGNOSIS; RISK FACTORS;

EID: 0032195225     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-199811000-00005     Document Type: Article

References (30)

1. Isles A, Maclusky I, Corey M, Gold R, Prober C, Fleming P, Levison H: Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr 1984, 104:206-210.
2. Hardy KA, McGowan KL, Fisher MC, Schidlow DV: Pseudomonas cepacia in the hospital setting: lack of transmission between cystic fibrosis patients. J Pediatr 1986, 109:51-54.
3. LiPuma JJ, Mortensen JE, Dasen SE, Edlind TD, Schidlow DV, Burns JL, Stull TL: Ribotype analysis of Pseudomonas cepacia from cystic fibrosis treatment centers. J Pediatr 1988, 113:859-862.
4. LiPuma JJ, Dasen SE, Nielson DW, Stull TL: Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet 1990, 336:1094-1096.
5. LiPuma JJ: Burkholderia cepacia: management issues and new insights. Clin Chest Med 1998, 19:473-486. A comprehensive review of the literature that the reader interested in greater detail may find useful.
6. Pegues DA, Schidlow DV, Tablan OC, Carson LA, Clark NC, Jarvis WR: Possible nosocomial transmission of Pseudomonas cepacia in patients with cystic fibrosis. Arch Pediatr Adolesc Med 1994, 148:805-812.
7. Drabick JA, Gracey EJ, Heidecker GJ, LiPuma JJ: Survival of Burkholderia cepacia on environmental surfaces. J Hosp Infect 1996, 32:267-276.
8. Humphreys H, Peckham D, Patel P, Knox A: Airborne dissemination of Burkholderia (Pseudomonas) cepacia from adult patients with cystic fibrosis. Thorax 1994, 49:1157-1159.
9. Shreve MR, Johnson SJ, Milla CE, Wielinski CL, Regelmann WE: PCR ribotyping and endonuclease subtyping in the epidemiology of Burkholderia cepacia infection. Am J Respir Crit Care Med 1997, 155:984-989. A very nice study that augments epidemiologic investigation with genotyping analyses to demonstrate risk of nosocomial acquisition of B. cepacia.
10. Hutchinson GR, Parker S, Pryor JA, Duncan-Skingle F, Hoffman PN, Hodson ME, et al.: Home-use nebulizers: a potential primary source of Burkholderia cepacia and other colistin-resistant, gram-negative bacteria in patients with cystic fibrosis. J Clin Microbiol 1996, 34:584-587.
11. Govan JRW, Deretic V: Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996, 60:539-574.
12. Hughes JE, Stewart J, Barclay GR, Govan JRW: Priming of neutrophil respiratory burst activity by lipopolysaccharide from Burkholderia cepacia. Infect Immunol 1997, 65:4281-4287.
13. Lewin LO, Byard PJ, Davis PB: Effect of Pseudomonas cepacia colonization on survival and pulmonary function of cystic fibrosis patients. J Clin Epidemiol 1990, 43:125-131.
14. LiPuma JJ, Marks-Austin KA, Holsclaw DS, Winnie GB, Gilligan PH, Stull TL: Inapparent transmission of Pseudomonas (Burkholderia) cepacia among patients with cystic fibrosis. Pediatr Infect Dis J 1994, 13:716-719.
15. Whitby PW, Dick HLN, Campbell PW, Tullis DE, Matlow A, Stull TL: Comparison of culture and PCR detection of Burkholderia cepacia in sputum of patients with cystic fibrosis. J Clin Microbiol 1998, 36:1642-1645.
16. Sun L, Jiang R-Z, Steinbach S, Holmes A, Campanelli C, Forstner J, et al.: The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain. Nature Med 1995, 1:661-666.
17. Mahenthiralingam E, Simpson DA, Speert DP: Identification and characterization of a novel DNA marker associated with epidemic Burkholderia cepacia strains recovered from patients with cystic fibrosis. J Clin Microbiol 1997, 35:808-816.
18. Vandamme P, Holmes B, Vancanneyt M, Coenye T, Hoste B, Coopman R, et al.: Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients: proposal of Burkholderia multivorans sp. nov. Int J Syst Bacteriol 1997, 47:1188-1200. Not the sort of manuscript that the clinician would find particularly easy reading, but this report describes a major advance in our understanding of B. cepacia, introducing the concept of the multiple species comprising the B. cepacia complex.
19. Mahenthiralingam E, Henry DA, Vandamme P, Campbell ME, Speert DP: Biochemical and genetic characteristics of epidemic strains of Burkholderia cepacia recovered from patients with cystic fibrosis [abstract 306]. Pediatr Pulmonol 1997, 14(suppl):290.
20. Ledson MJ, Gallagher MJ, Corkill JE, Hart CA, Walshaw MJ: Cross infection between cystic fibrosis patients colonised with Burkholderia cepacia. Thorax 1998, 53:432-436. An important case report that raises serious concerns about the practice of cohorting based on colonization status. The potential for implementing infection control policies that take into account strain genotype/phenotype is discussed.
21. Holmes A, Govan J, Goldstein R: Agricultural use of Burkholderia (Pseudomonas) cepacia: a threat to human health? Emerg Infect Dis 1998, 4:221-227. A recent synopsis that will introduce the reader to the issues and concerns involved in the commercial use of B. cepacia.
22. Govan JRW, Vandamme P: Agricultural and medical microbiology: a time for bridging gaps. Microbiology 1998, 144:2373-2375.
23. Lessie TG, Hendrickson W, Manning BD, Devereux R: Genomic complexity and plasticity of Burkholderia cepacia. FEMS Microbiol Lett 1996, 144:117-128.
24. Govan JRW, Burns JL, Speert DP: Common questions about Burkholderia cepacia. Bromley, UK: CF Trust; 1998. A concise, easy to read set of questions and answers about B. cepacia, composed by three highly regarded experts in the field. It is written as an educational resource and would be suitable for distribution to patients, parents, and CF caregivers.
25. LiPuma JJ, Henry D, Mehar F, Speert DP, Saiman L: Misidentification of Burkholderia cepacia [abstract 1810]. Pediatr Res 1997, 41:304A.
26. Simpson IN, Finlay J, Winstanley DJ, Dewhurst N, Nelson JW, Butler SL, Govan JR: Multi-resistant isolates possessing characteristics of both Burkholderia (Pseudomonas) cepacia and Burkholderia gladioli from patients with cystic fibrosis. J Antimicrob Chemother 1994, 34:353-361.
27. Govan JRW, Brown PH, Maddison J, Doherty CJ, Nelson JW, Dodd M, et al.: Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet 1993, 342:15-19.
28. Cazzola G, Amalfitano G, Tonolli E, Perazzoli C, Piacentini I, Mastella G: Burkholderia (Pseudomonas) cepacia epidemiology in a cystic fibrosis population: a genome finger-printing study. Acta Paediatr 1996, 85:554-557.
29. Ledson MJ, Gallagher MJ, Walshaw MJ: Chronic Burkholderia cepacia bronchiectasis in a non-cystic fibrosis individual. Thorax 1998, 53:430-432.
30. Mortensen JE, Fisher MC, LiPuma JJ: Recovery of Pseudomonas cepacia and other Pseudomonas species from the environment. Infect Control Hosp Epidemiol 1995, 16:30-32.